Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine

Schizophr Res. 2012 Oct;141(1):22-8. doi: 10.1016/j.schres.2012.07.014. Epub 2012 Aug 11.

Abstract

Background: Imaging evidence indicates that brain alterations are primary to the full-blown onset of schizophrenia and seem to progress across time. The potential effects of antipsychotic medication on brain structure represent a key factor in understanding brain changes in psychosis. We aimed to investigate the effects of low doses of haloperidol, risperidone and olanzapine on cortical thickness.

Method: We investigated the effects of risperidone (N=16), olanzapine (N=18) and low doses of haloperidol (N=18) in cortical thickness changes during 1-year follow-up period in a large and heterogeneous sample of schizophrenia spectrum patients. The relationship between cortical thickness changes and clinical and cognitive outcome was also assessed. A group of 45 healthy volunteers was also longitudinally evaluated. Magnetic resonance imaging brain scans (1.5T) were obtained and images were analyzed by using BRAINS2.

Results: There were no significant effects of time (F(1,47)<1.66; P>0.204), treatment group (F(2,47)<1.47; P>0.242) or group-by-time interaction (F(2,47)<1.82; P>0.174) for any of the cortical thickness variables. When the group of healthy controls was included in the analyses, it is of note that group-by-time interaction showed a significant result for the frontal lobe at trend level (F(3,81)=2.686; P=0.052). After the Bonferroni adjustment for multiple comparisons, there were no significant associations between changes in cortical thickness and clinical and cognitive outcome.

Conclusions: Low doses of haloperidol, risperidone, and olanzapine seem to equally affect gray matter cortical thickness, overall and lobes, at the medium-term (1 year). The clinical effectiveness of treatments was not significantly related to changes in cortical thickness.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Analysis of Variance
  • Antipsychotic Agents / pharmacology*
  • Antipsychotic Agents / therapeutic use
  • Benzodiazepines / pharmacology
  • Benzodiazepines / therapeutic use
  • Cerebral Cortex / drug effects*
  • Cognition Disorders / etiology
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Haloperidol / pharmacology
  • Haloperidol / therapeutic use
  • Humans
  • Image Processing, Computer-Assisted
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Olanzapine
  • Psychiatric Status Rating Scales
  • Retrospective Studies
  • Risperidone / pharmacology
  • Risperidone / therapeutic use
  • Schizophrenia / complications
  • Schizophrenia / drug therapy
  • Schizophrenia / pathology*
  • Young Adult

Substances

  • Antipsychotic Agents
  • Benzodiazepines
  • Haloperidol
  • Risperidone
  • Olanzapine